Check for updates

OPEN ACCESS

EDITED BY Livio Luzi, University of Milan, Italy

REVIEWED BY Balazs Gaszner, University of Pécs, Hungary Shady Abohashem, Harvard Medical School, United States

*CORRESPONDENCE Sungeun Kim Seiong@korea.ac.kr

SPECIALTY SECTION

This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology

RECEIVED 17 September 2022 ACCEPTED 16 December 2022 PUBLISHED 05 January 2023

CITATION

Pahk K, Joung C, Kwon HW and Kim S (2023) Chronic physical exercise alleviates stress-associated amygdala metabolic activity in obese women: A prospective serial ¹⁸F-FDG PET/CT study. *Front.* Endocrinol. 13:1046838. doi: 10.3389/fendo.2022.1046838

COPYRIGHT

© 2023 Pahk, Joung, Kwon and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License

(CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Chronic physical exercise alleviates stress-associated amygdala metabolic activity in obese women: A prospective serial ¹⁸F-FDG PET/CT study

Kisoo Pahk^{1,2}, Chanmin Joung³, Hyun Woo Kwon² and Sungeun Kim^{2*}

¹Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, South Korea, ²Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea, ³Graduate School of Biomedical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States

Background: Psychological stress is considered as a major risk factor for cardiovascular disease (CVD). Chronic exercise is known to reduce CVD risk partly through attenuating psychological stress. Obesity has been linked with increased levels of psychological stress. We aimed to prospectively evaluate whether physical exercise could alleviate stress-associated amygdala metabolic activity, assessed by ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in women with obesity.

Material and methods: A total of 43 participants were enrolled in this study. Twenty-three obese women were participated in a physical exercise program 5 days per week for 3 months. The exercise program consisted of aerobic exercise and resistance training. Serial ¹⁸F-FDG PET/CT was taken before the start of physical exercise program (baseline) and after finishing the program (post-exercise). A total of 20 participants who underwent ¹⁸F-FDG PET/CT for general health check-up were enrolled as non-obese control group. Brain amygdala activity (AmygA) was calculated as maximum standardized uptake value (SUVmax) of amygdala normalized to mean SUV of temporal lobe.

Results: Chronic physical exercise significantly reduced AmygA and improved body adiposity and systemic inflammation. AmygA was highest in baseline, intermediate in post-exercise, and lowest in non-obese control group (0.76 \pm 0.17, 0.61 \pm 0.1, 0.52 \pm 0.09, p < 0.001). Furthermore, physical exercise also abrogated the association of AmygA with systemic inflammation.

Conclusions: Chronic physical exercise reduced stress-associated amygdala metabolic activity and broke its association with systemic inflammation in obese women. This study could explain the putative mechanism underlying the health beneficial effect of exercise on CVD *via* attenuation of stress neurobiology.

KEYWORDS

obesity, cardiovascular disease, amygdala, stress, exercise, positron-emission tomography

Introduction

Psychological stress, an essential component of life in human beings, is the physiologic emotional response to physiological-, social-, and environmental stimuli stressors (1). In recent years, psychological stress has been increasingly considered as an independent risk factor for cardiovascular disease (CVD), which is the leading cause of global death (2, 3). Furthermore, psychological stress is also associated with well-known traditional CVD risk factors such as obesity and hypertension (4, 5). Psychological stress has been considered as one key factor in the development of obesity and people with obesity show elevated levels of psychological stress (4, 5). However, detailed underlying mechanism that translate psychological stress into CVD risks remains to be fully explored.

Recently, efforts to elucidate the underlying mechanism of stress and CVD risk have focused on specific brain region which may activated by psychological stress (6). Amygdala, a core part of brain's salience network, is known to regulate pathophysiologic and behavioral response to psychological stress with accompanied increased in pro-inflammatory cytokine levels (7, 8). Accumulating evidence have suggested that resting amygdala activity (AmygA) can be reproducibly measured with high reliability using ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) (9-11). AmygA has been well correlated with stress-related psychometric questionnaires (10, 11) and was associated with greater circulating systemic inflammatory surrogate markers and with worsening atherosclerotic plaque vulnerability (10). Furthermore, AmygA independently predicts subsequent CVD events (9, 12). Thus collectively, AmygA can reflect the risk burden of CVD imposed by psychological stress.

Chronic physical exercise is well-known to exert substantial health benefits and attenuates CVD risk, partly through its antiinflammatory activities on brain, adipose tissue, and hematopoietic organs (13). In addition, chronic exercise also reduces the level of stress, as assessed by psychometric questionnaires, and attenuates systemic inflammation (14). However, little is known about the effect of chronic physical exercise on stress-associated neurobiological activity. As AmygA has been associated with systemic inflammation, which is mitigated by exercise, we hypothesized that AmygA could also be affected by chronic physical exercise.


In present study, we aimed to investigate whether chronic physical exercise could alleviate AmygA, evaluated by ¹⁸F-FDG PET/CT in obese women and could affect the relationship between AmygA and systemic inflammation.

Materials and methods

Study design and population

This study was composed of two types of investigations. As shown in Figure 1, the first was a longitudinal study exploring the temporal change of AmygA after chronic physical exercise in obese women. The second was a cross-sectional study comparing AmygA between obese women who completed the chronic physical exercise program and non-obese control group.

The longitudinal study population was recruited between June 2008 to March 2009 from the local community health center. Obesity was defined as a body mass index (BMI) of at least 25 kg/ m², according to the guideline for the management of obesity in Korea (15). Participants with a history of malignancy, those who had previously diagnosed CVD, hypertension (\geq stage 2), uncontrolled diabetes mellitus, autoimmune disease, severe hepatic, or renal disease, and those had taken any medications that could affect systemic inflammation within 6 months were excluded. Finally, a total of 23 participants were enrolled in this longitudinal study. They all underwent scheduled exercise program under supervision (5 times a week for 3 months) and without restricting diet. ¹⁸F-FDG PET/CT was performed before the start of exercise program (baseline) and after completion of 3 months of exercise program (post-exercise). In cross-sectional study, age-and sex matched non-obese control participants who underwent ¹⁸F-FDG PET/CT for general health check-up were enrolled from the



Health Promotion Center at our hospital between January 2021 and May 2021. The exclusion criteria were same as the above longitudinal study. In total, 20 women were enrolled as nonobese control group. This study was approved by the Ethical

Committee and Institutional Review Board of Korea University

Hospital (Approval No. GR0888-005) and all participants provided

Exercise protocol

written informed consent.

The exercise program was designed to include aerobic- with subsequent muscle-resistant exercise, recommend by the American Heart Association (AHA) and the American College of Sports Medicine (ACSM) to improve and keep health (16). For aerobic exercise, participants engaged in 30 min of moderate-intensity activity (walking at very brisk pace at 4 mph) followed by 20 mins of vigorous-intensity activity (running at 7 mph). Using metabolic equivalents (METs), intensity between 3 and 6 METs was considered moderateintensity and over 6 METs was considered vigorous-intensity, respectively (16). For muscle-resistant exercise, participants engaged in 8-10 exercises involving major muscle groups with 8 to 12 repetitions, as previously described (16).

Anthropometric and laboratory measurements

BMI was determined as weight/height squared (kg/m²). Waist circumference was measured at the narrowest point between the last rib and the top of iliac crest after normal exhaling. Hip circumference was measured at the maximum protrusion of buttocks. Blood samples were obtained after 12-h overnight fasting, and analyzed with chemistry analyzer (Hitachi 747, Hitachi, Tokyo, Japan). The levels of high-sensitivity C-reactive protein (hsCRP) were analyzed with Dade Behring BNII analyzer (Siemens, Munich, Germany).

¹⁸F-FDG PET/CT imaging acquisition protocol

¹⁸F-FDG was injected intravenously at a dose of 5.29 MBq/ kg after an overnight fast for at least 8 h. PET/CT images were acquired 1 h after tracer injection with an integrated scanner (GEMINI TF, Philips Medical Systems, Cleveland, OH, USA). Non-contrast-enhanced CT (120 kVp, 50mA, 4 mm thickness) was performed for attenuation correction before PET scan. The scanning range was set from vertex of skull to proximal thigh. All PET images were reconstructed by 3D-ordered iterative algorithm (3 iterations with 33 subsets, matrix size 144×144).

Image analysis

Images were analyzed by two fully trained nuclear medicine radiologists (KP and HWK), who were blinded to clinical data, using a commercially available workstation (Extended Brilliance Workspace version 3.5, Philips Healthcare, Eindhoven, Netherlands). ¹⁸F-FDG uptakes were quantified by using standardized uptake value (SUV) which is defined as the tissue radioactivity concentration (MBq/g) in a region of interest (ROI) normalized for the injected dose (MBq) and the total body weight (g).

The amygdalae, which are the part of brain's limbic system deep within the temporal lobe, forming the ventral, superior and medial aspect of the inferior horn of the lateral ventricle, were recognized by anatomical landmarks which were described in previous studies (9-12). In detail, the anterior and the posterior boundaries were identified as the inferior aspect of the lateral ventricles and the crus of fornix forming anterior to the basilar artery, respectively. Both lateral and inferior boundary were determined by the internal capsule. Next, for the evaluation of AmygA, circular ROIs were placed on both left and right amygdala and SUVs were measured, as previously described (9-12). AmygA was defined by dividing the maximum SUVs (SUVmax) in each amygdala by the mean SUVs in ipsilateral brain temporal lobes for normalization of background activity. The primary measure of AmygA was the highest AmygA between the two amygdalae (9-12).

Metabolic activities in hematopoietic system such as spleen and bone marrow (BM) are the well-known surrogate markers to reflect the systemic inflammation (17–19). ROIs were placed within spleen and vertebrae (L3 to L5) to measure spleen and BM metabolic activity. Spleen SUVmax was defined as the average SUVmax of spleen on all axial slices. BM SUVmax was defined as the average SUVmax of L3 to L5 vertebrae (18, 19).

Statistical analysis

Data are presented as mean and standard deviation. Shapirowilk test was used to determine the normalcy of variables. Paired *t*-test or Wilcoxon signed-rank test was used for comparison between baseline and post-exercise. For comparison of two groups, Student's *t*-test, or Mann–Whitney *U* test was used. The Pearson Chi squared (χ 2) test or Fisher's exact test, Spearman's correlation analysis, univariate-, and multivariate linear regression were also performed as statistical methods. MedCalc software version 18.5 (MedCalc Software Ltd, Ostend, Belgium) and SPSS software version 17.0 (SPSS Inc, Chicago, IL, USA) were used for data analysis. A *p*-value equal or less than 0.05 was considered statistically significant.

Results

All enrolled obese women have completed the scheduled exercise program and detailed baseline characteristics of the study population are presented in Table 1. As shown in Figure 2, a 3-month of chronic exercise significantly alleviated blood pressure and body adiposity.

Chronic physical exercise reduces AmygA and systemic inflammation in obese women


Chronic physical exercise significantly decreased Amyg SUVmax (3.35 ± 0.9 to 2.7 ± 0.62 , p < 0.001, Figures 3A, B, D) and AmygA (0.76 ± 0.17 to 0.61 ± 0.1 , p < 0.001, Figures 3A, B, F). In contrast, Temporal SUVmean was not significantly changed (4.44 ± 0.75 to 4.44 ± 0.59 , p = 0.952, Figure 3E). Physical exercise also reduced surrogate markers of systemic inflammation such as spleen SUVmax, BM SUVmax, and hsCRP (Figure 2). The effect of physical exercise on other clinical parameters is presented on Supplementary Table 1.

Comparison between post-exercise obese women and control participants

AmygA was significantly highest in baseline, intermediate in post-exercise, and lowest in control group (Figures 3A, B, C, F). Although, exercise reduced body adiposity and systemic inflammation, post-exercise obese women still showed

TABLE 1 Baseline characteristics of obese women.

Baseline characteristics	n = 23
Age (years)	46 ± 8.0
Height (cm)	156.8 ± 5.5
Alcohol drinking, n (%)	8 (34.8)
Smoking (current), n (%)	0 (0)
Medication, n (%)	0 (0)
Diabetes, n (%)	0 (0)
Dyslipidemia, n (%)	7 (30.4)
Hypertension (stage I), n (%)	4 (17.4)
Menopause, n (%)	12 (52.2)
Age and height were expressed as mean \pm standard deviation.	



(A–G). BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; SUVmax, maximum standardized uptake value; BM, bone marrow; hsCRP, high-sensitivity C-reactive protein. *P*-values of BMI, WC, SBP, DBP, spleen SUVmax, BM SUVmax, and hsCRP between baseline and post-exercise obese women were determined using paired *t*-test. *P*-values of BMI, WC, SBP, DBP, spleen SUVmax, and BM SUVmax between post-exercise obese women and control group were determined using Student's *t*-test. *P*-value of hsCRP between post-exercise obese women and control group were determined using Student's *t*-test. *P*-value of hsCRP between post-exercise obese women and control group was determined using Mann–Whitney *U* test. *Statistically significant difference.


significant higher BMI, waist circumference, hsCRP, spleen SUVmax, and BM SUVmax than the control participants (Figures 2A–G). Comparison of other clinical parameters between post-exercise obese women and control participants is presented on Supplementary Table 2.

Association between AmygA and systemic inflammation in obese women at baseline

AmygA exhibited significant correlation with hsCRP and BM SUVmax in obese women at baseline, whereas it showed no significant correlation with systemic inflammation surrogate markers in control participants (Table 2). As shown in Table 3, AmygA presented significant association with higher body adiposity, lower high-density lipoprotein cholesterol (HDL-C), higher BM SUVmax, and higher hsCRP. In further multivariate analysis, AmygA showed significant association with higher hsCRP. Thus, based on these findings, we concluded that AmygA was significantly associated with systemic inflammation in obese women.

Association between AmygA and systemic inflammation at post-exercise

We next monitored changes in the association between AmygA and systemic inflammation by chronic physical exercise. As shown in Table 2, the correlation between AmygA and systemic inflammation was no longer significant at postexercise. In addition, AmygA became not associated with systemic inflammation after completion of chronic physical exercise in obese women (Table 4).



Chronic physical exercise significantly reduced the amygdala activity (AmygA) in obese women. Representative fused images of ¹⁶F-FDG PET/CT at baseline - (A), post-exercise obese women (B), and non-obese control group (C). Changes in Amyg SUVmax (D) and Temporal SUVmean (E) between baseline and post-exercise obese women. Changes in AmygA between baseline and post-exercise obese women and non-obese control group (F). Amyg SUVmax, maximum standardized uptake value of amygdala; Temporal SUVmean, mean standardized uptake value of temporal lobe; AmygA, Amyg SUVmax, Temporal SUVmean. The circular ROI indicates amygdala, and the arrowhead indicates temporal lobe. *P*-values of Amyg SUVmax, Temporal SUVmean, and AmygA between baseline and post-exercise obese women and control group was determined using Student's t-test. *Statistically significant difference.

Association between changes in the levels of AmygA and systemic inflammation between baseline and post-exercise

As shown in Table 5, changes in the levels of AmygA were significantly associated with changes in the levels of BM SUVmax and hsCRP by both univariate and multivariate analyses. Thus, the impact of exercise on reducing AmygA was significantly associated with reducing systemic inflammation in obese women.

Discussion

In the present study, for the first time in human beings, we prospectively investigated the anti-stress effect of chronic physical exercise on the stress-associated metabolic activity of amygdala as assessed by ¹⁸F-FDG PET/CT in obese women. The present study clearly revealed that AmygA, the metabolic activity of amygdala, was elevated in obese women and was alleviated by a 3-month of physical exercise. Furthermore, physical exercise also abolished its association with systemic inflammation in obese women.

Accumulating evidence have reported that increased neural activity of amygdala can promote the development and maintenance of obesity under conditions of stress in both animal and human studies (20–22). Using genetically modified animals, Ip et al. (20) have found that increased expression of neuropeptide-Y in amygdala under stress condition, increases food consumption and decreases energy expenditure thereby accelerating obesity. In contrast, some previous animal and human studies have reported that stress facilitates the development of obesity independently of food consumption

(23–26). Thus, these data suggest that elevated food intake may not be a sole contributor to stress-associated obesity.

Recently, Ishai et al. (22) report that increased neural activity of amygdala is associated with increased leukopoietic activity in bone marrow thereby upregulating systemic inflammation, which contributes to obesity development. This finding is robustly supported by previous human imaging studies by using ¹⁸F-FDG PET/CT that AmygA is closely associated with BM SUVmax and hsCRP (9–11), which are also consistent with our results. Thus, systemic inflammation could be a strong mediator of the association between stress-associated neurobiological activity and obesity.

The emotional response to psychological stress has been well known to activate the projections from amygdala to brainstem thereby stimulating hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, which lead to elevate the levels of circulating glucocorticoids and accelerate inflammatory cell output in the bone marrow (27–30). Exercise training reduces the levels of circulating glucocorticoids and attenuates the reactivity of sympathetic nervous system to psychological stress (14, 31). Supporting these previous findings, the current study demonstrated that chronic physical exercise reduced both AmygA and surrogate markers of systemic inflammation.

AmygA was decreased with physical exercise down to about 20% of baseline, whereas post-exercise women still showed significant higher levels of AmygA and systemic inflammation than non-obese control participants. However, interestingly, the significant association between AmygA and systemic inflammation in obese women was disappeared by chronic physical exercise. Following that, AmygA was not associated with the systemic inflammation in non-obese control participants. Thus, although the detailed underlying mechanism remains unclear, our findings could support the beneficial anti-inflammatory effect of chronic physical exercise

TABLE 2 Correlation analysis between AmygA and surrogate markers for systemic inflammation.

Paramotor	Amy	AmygA	
Parameter		p	
hsCRP	0.688	< 0.001*	
Spleen SUVmax	0.378	0.076	
BM SUVmax	0.49	0.018*	
hsCRP	0.204	0.351	
Spleen SUVmax	0.366	0.086	
BM SUVmax	0.192	0.38	
hsCRP	-0.212	0.369	
Spleen SUVmax	0.144	0.633	
BM SUVmax	-0.293	0.21	
	Spleen SUVmax BM SUVmax hsCRP Spleen SUVmax BM SUVmax hsCRP Spleen SUVmax	ParameterrhsCRP0.688Spleen SUVmax0.378BM SUVmax0.49hsCRP0.204Spleen SUVmax0.366BM SUVmax0.192hsCRP-0.212spleen SUVmax0.144	

	Univariate	Multivariate		
Variable	Coefficients (95% CI)	p	Coefficients (95% CI)	p
Age	0.002 (-0.008 - 0.011)	0.739		
BMI (kg/m ²)	0.041 (0.011 - 0.071)	0.01*	-0.001 (-0.054 - 0.053)	0.979
Waist circumference (cm)	0.014 (0.002 - 0.027)	0.025*	0.001 (-0.017 - 0.018)	0.948
Hip circumference (cm)	0.017 (0.004 - 0.03)	0.013*	0.012 (-0.007 - 0.032)	0.186
AST (IU/L)	0 (-0.02 - 0.02)	0.98		
ALT (IU/L)	0.006 (-0.013 - 0.026)	0.515		
Triglyceride (mg/dL)	0.001 (-0.001 - 0.003)	0.376		
Total cholesterol (mg/dL)	-0.001 (-0.003 - 0.002)	0.611		
HDL-C (mg/dL)	-0.006 (-0.013 - 0)	0.045*	-0.005 (-0.01 - 0.001)	0.116
LDL-C (mg/dL)	-6.572E-005 (-0.003 – 0.003)	0.961		
Glucose (mg/dL)	-0.001 (-0.01 - 0.008)	0.856		
SBP (mmHg)	0.003 (-0.002 - 0.007)	0.192		
DBP (mmHg)	0.004 (-0.002 - 0.011)	0.199		
Spleen SUVmax	0.227 (-0.028 - 0.482)	0.079		
BM SUVmax	0.295 (0.031 - 0.558)	0.03*	0.009 (-0.347 - 0.365)	0.957
hsCRP (mg/L)	0.027 (0.008 - 0.046)	0.007*	0.023 (0.004 - 0.042)	0.021*

TABLE 3 Univariate- and multivariate analysis with AmygA as a dependent variable at baseline obese women .

BMI, body mass index; AST, aspartate transaminase; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; SUVmax, maximum standardized uptake value; BM, bone marrow; hsCRP, high-sensitivity C-reactive protein; CI, confidence interval.

*Statistically significant difference.

in obesity and could further illuminate a potential mechanism that emphasizes anti-inflammatory effect of chronic exercise through affecting stress-associated amygdala metabolic activity in obese women.

A growing body of evidence has emerged on the therapeutic potential of stress reduction on CVD (32). Stress reduction has demonstrated carotid plaque stabilization in older populations and reduced adverse CVD events from a randomized controlled trial (32, 33). Furthermore, based on these findings, the American Heart Association announced a statement that stress reduction has a potential benefit in CVD and encouraged further research (34). Considering these findings, assessment of stressrelated neurobiological activity for monitoring treatment response and risk stratification could be crucial for management of stress on CVD. Given that amygdala is a main component of stress response, we believe that AmygA assessed by ¹⁸F-FDG PET/CT could be used as a surrogate marker of stress-related amygdala metabolic activity thereby measuring stress levels in clinical field.

Our study has several limitations. First, despite being a prospective design, this study was performed with small number of participants, which have a possibility to induce selection bias. Further prospective study with large populations is warranted to confirm our findings. Second, due to limited image resolution of current ¹⁸F-FDG PET/CT, we could not evaluate the other brain regions related to stress-neural circuit such as hippocampus. Third, we were unable to measure the direct markers of sympathetic nervous system and HPA axis activity. Fourth, we used one fixed exercise training program in this study. Variable exercise programs, modulating type, intensity, and period of exercise, could have different effect on AmygA. Furthermore, we recruited obese women between 2008 and 2009, and applied exercise program based on the AHA/ACSM guideline which was published in 2007. However, recently, updated guideline has been published since 2018 (35). Further study with updated exercise guideline is needed to confirm our findings. Fifth, we could not control all the lifestyle factors such as dietary habits and sleeping time which might potentially affect the AmygA. Sixth, current study was conducted on obese women. Further studies with balanced gender distribution are needed to evaluate gender-specific differences of AmygA in response to exercise. Finally, as shown in Table 1, 34.8% of obese women reported that they consumed alcohol. However, we could not evaluate the frequency and amount of alcohol use. Chronic alcohol consumption is known to affect amygdala (36, 37). Thus, alcohol consumption could be a confounding factor for interpreting AmygA. Nevertheless, our findings counterbalanced these

	Univariate	Multivariate			
Variable	Coefficients (95% CI)	p	Coefficients (95% Cl)	p	
Age	-0.002 (-0.008 - 0.004)	0.44			
BMI (kg/m ²)	0.01 (-0.008 - 0.028)	0.27			
Waist circumference (cm)	0.004 (-0.003 - 0.012)	0.245			
Hip circumference (cm)	0.001 (-0.009 - 0.011)	0.857			
AST (IU/L)	0.005 (-0.004 - 0.014)	0.263			
ALT (IU/L)	0.008 (-0.002 - 0.019)	0.122			
Triglyceride (mg/dL)	0 (-0.001 - 0.001)	0.536			
Total cholesterol (mg/dL)	0.001 (-0.001 - 0.002)	0.412			
HDL-C (mg/dL)	-0.004 (-0.009 - 0.001)	0.133			
LDL-C (mg/dL)	0.001 (0 - 0.002)	0.24			
Glucose (mg/dL)	0.004 (0 - 0.009)	0.063			
SBP (mmHg)	0.001 (-0.004 - 0.005)	0.81			
DBP (mmHg)	0 (-0.006 – 0.006)	0.899			
Spleen SUVmax	0.194 (-0.001 - 0.39)	0.051			
BM SUVmax	0.104 (-0.104 - 0.311)	0.311			
hsCRP (mg/L)	0.013 (-0.02 - 0.047)	0.42			

TABLE 4 Univariate- and multivariate analysis with AmygA as a dependent variable at post-exercise obese women.

interval. *Statistically significant difference.

TABLE 5 Univariate- and multivariate analysis for changes in the levels of AmygA with changes in the levels of other variables on obese women.

	Univariate	Univariate		Multivariate	
Variable	Coefficients (95% Cl)	p	Coefficients (95% CI)	p	
BMI (kg/m ²)	0.005 (-0.058 - 0.069)	0.867			
Waist circumference (cm)	0 (-0.014 - 0.015)	0.97			
Hip circumference (cm)	0.017 (-0.018 - 0.052)	0.325			
AST (IU/L)	-0.006 (-0.017 - 0.005)	0.269			
ALT (IU/L)	-0.01 (-0.025 - 0.004)	0.147			
Triglyceride (mg/dL)	0.001 (-0.001 - 0.002)	0.289			
Total cholesterol (mg/dL)	0 (-0.003 - 0.003)	0.906			
HDL-C (mg/dL)	-0.002 (-0.013 - 0.01)	0.779			
LDL-C (mg/dL)	-0.001 (-0.004 - 0.001)	0.259			
Glucose (mg/dL)	-0.003 (-0.011 - 0.005)	0.422			
SBP (mmHg)	0.002 (-0.003 - 0.008)	0.421			
DBP (mmHg)	0.002 (-0.008 - 0.012)	0.634			
	1	I		(Continued)	

TABLE 5 Continued

	Univariate	Univariate		Multivariate	
Variable	Coefficients (95% CI)	р	Coefficients (95% CI)	p	
Spleen SUVmax	0.276 (-0.065 - 0.617)	0.107			
BM SUVmax	0.312 (0.055 - 0.569)	0.02*	0.25 (0.003 - 0.498)	0.048*	
hsCRP (mg/L)	0.022 (0.003 - 0.04)	0.022*	0.017 (0 - 0.035)	0.05*	

BMI, body mass index; AST, aspartate transaminase; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; SUVmax, maximum standardized uptake value; BM, bone marrow; hsCRP, high-sensitivity C-reactive protein; CI, confidence interval.

*Statistically significant difference.

limitations by using a non-invasive functional imaging modality to measure the metabolic activity of amygdala, to investigate the health-protective effect of exercise on stress-associated brain neural activity in obese women.

Taken together, we provide strong evidence that the 3month of physical exercise reduced stress-associated amygdala metabolic activity, which was defined as AmygA and measured by ¹⁸F-FDG PET/CT and broke its association with systemic inflammation in obese women. Despite preliminary data, these findings could support the putative health protective mechanism underlying between exercise and CVD *via* stress reduction. In addition, our study further highlights the promising role of AmygA as a surrogate marker of stress-related amygdala metabolic activity for evaluating anti-stress effect of therapeutic interventions targeted to stress reduction.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethical Committee and Institutional Review Board of Korea University Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization: KP and SK. Data curation: KP, CJ, and HWK. Formal analysis: KP, CJ, and HWK. Investigation: KP and

CJ. Methodology: KP, CJ, and HWK. Project administration: KP and SK. Validation: KP and HWK. Visualization: KP and CJ. Writing-original draft: KP. Writing-review & editing: SK. Supervision: SK. Funding acquisition: SK. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by grant of KOREA HYDRO & NUCLEAR POWER CO., LTD (No. 22-Tech-10). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2022.1046838/full#supplementary-material

References

1. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL, et al. Approaching health disparities from a population perspective: the national institutes of health centers for population health and health disparities. *Am J Public Helath* (2008) 98:1608–15. doi: 10.2105/AJPH.2006.102525

2. Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet (2007) 370:1089-100. doi: 10.1016/S0140-6736(07)61305-1

3. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nat Rev Cardiol* (2018) 15:215–29. doi: 10.1038/nrcardio.2017.189

4. Scott KA, Melhorn SJ, Sakai RR. Effects of chronic social stress on obesity. *Curr Obes Rep* (2012) 1:16–25. doi: 10.1007/s13679-011-0006-3

5. Rod NH, Grønbaek M, Schnohr P, Prescott E, Kristensen TS. Perceived stress as a risk factor for changes in health behaviour and cardiac risk profile: a longitudinal study. *J Intern Med* (2009) 266:467–75. doi: 10.1111/j.1365-2796.2009.02124.x

6. Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging: moving toward a model of behavioral and biological mechanisms. *Psychol Bull* (2011) 137:959–97. doi: 10.1037/a0024768

 Lagraauw HM, Kuiper J, Bot I. Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies. *Brain Behav Immun* (2015) 50:18–30. doi: 10.1016/ j.bbi.2015.08.007

8. Muscatell KA, Dedovic K, Slavich GM, Jarcho MR, Breen EC, Bower JE, et al. Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. *Brain Behav Immun* (2015) 43:46–53. doi: 10.1016/j.bbi.2014.06.201

9. Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, et al. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. *Lancet* (2017) 389:834–45. doi: 10.1016/S0140-6736(16)31714-7

10. Kang DO, Eo JS, Park EJ, Nam HS, Song JW, Park YH, et al. Stressassociated neurobiological activity is linked with acute plaque instability via enhanced macrophage activity: a prospective serial 18F-FDG-PET/CT imaging assessment. Eur Heart J (2021) 42:1883–95. doi: 10.1093/eurheartj/ehaa1095

11. Pahk K, Kwon HW, Joung C, Kim S. Stress-related amygdala metabolic activity is associated with low bone mineral density in postmenopausal women: A pilot ¹⁸F-FDG PET/CT study. *Front Endocrinol (Lausanne)* (2021) 12:719265. doi: 10.3389/fendo.2021.719265

12. Goyal A, Dey AK, Chaturvedi A, Elnabawi YA, Aberra TM, Chung JH, et al. Chronic stress-related neural activity associates with subclinical cardiovascular disease in psoriasis: a prospective cohort study. *JACC Cardiovasc Imaging* (2020) 2 Pt 1):465–77. doi: 10.1016/j.jcmg.2018.08.038

13. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. *Nat Rev Immunol* (2011) 11:607–15. doi: 10.1038/nri3041

14. O'Keefe EL, O'Keefe JH, Lavie CJ. Exercise counteracts the cardiotoxicity of psychosocial stress. *Mayo Clin Proc* (2019) 94:1852-64. doi: 10.1016/j.mayocp.2019.02.022

15. Kim MK, Lee WY, Kang JH, Kang JH, Kim BT, Kim SM. Et al; 2014 clinical practice guidelines for overweight and obesity in Korea. *Endocrinol Metab (Seoul)* (2014) 29:405–9. doi: 10.3803/EnM.2014.29.4.405

16. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American college of sports medicine and the American heart association. *Circulation* (2007) 116:1081–93. doi: 10.1161/CIRCULATIONAHA.107.185649

17. Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. *JACC Cardiovasc Imaging* (2015) 8:121–30. doi: 10.1016/j.jcmg.2014.10.009

18. Kim EJ, Kim S, Kang DO, Seo HS. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging. *Circ Cardiovasc Imaging* (2014) 7:454–60. doi: 10.1161/CIRCIMAGING.113.001093

19. Pahk K, Kim EJ, Joung C, Seo HS, Kim S. Association of glucose uptake of visceral fat and acute myocardial infarction: a pilot $^{18}{\rm F-FDG}$ PET/CT study. Cardiovasc Diabetol (2020) 19:145. doi: 10.1186/s12933-020-01115-3

20. Ip CK, Zhang L, Farzi A, Qi Y, Clarke I, Reed F, et al. Amygdala NPY circuits promote the development of accelerated obesity under chronic stress conditions. *Cell Metab* (2019) 30:111–28. doi: 10.1016/j.cmet.2019.04.001

21. Martín-Pérez C, Contreras-Rodríguez O, Verdejo-Román J, Vilar-López R, González-Pérez R, Verdejo-García A. Stressing diets? amygdala networks, cumulative cortisol, and weight loss in adolescents with excess weight. *Int J Obes* (*Lond*) (2020) 44:2001–10. doi: 10.1038/s41366-020-0633-4

22. Ishai A, Osborne MT, Tung B, Wang Y, Hammad B, Patrich T, et al. Amygdalar metabolic activity independently associates with progression of visceral adiposity. *J Clin Endocrinol Metab* (2019) 104:1029–38. doi: 10.1210/jc.2018-01456

23. Karagiannides I, Golovatscka V, Bakirtzi K, Sideri A, Salas M, Stavrakis D, et al. Chronic unpredictable stress regulates visceral adipocyte-mediated glucose metabolism and inflammatory circuits in male rats. *Physiol Rep* (2014) 2:e00284. doi: 10.14814/phy2.284

24. Aschbacher K, Kornfeld S, Picard M, Puterman E, Havel PJ, Stanhope K, et al. Chronic stress increases vulnerability to diet-related abdominal fat, oxidative stress, and metabolic risk. *Psychoneuroendocrinology* (2014) 46:14–22. doi: 10.1016/j.psyneuen.2014.04.003

25. Stewart-Knox B, Duffy M E, Bunting B, Parr H, Vas de Almeida MD, Gibney M. Associations between obesity (BMI and waist circumference) and sociodemographic factors, physical activity, dietary habits, life events, resilience, mood, perceived stress and hopelessness in healthy older europeans. *BMC Public Health* (2012) 12:424. doi: 10.1186/1471-2458-12-424

26. Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. *BMJ* (2006) 332:521-5. doi: 10.1136/bmj.38693.435301.80

27. Follis SL, Bea J, Klimentidis Y, Hu C, Crandall C, Garcia DO, et al. Psychosocial stress and bone loss among postmenopausal women: results from the women's health initiative. *J Epidemiol Community Health* (2019) 73:888–92. doi: 10.1136/jech-2019-212516

28. Wippert PM, Rector M, Kuhn G, Wuertz-Kozak K. Stress and alterations in bones: an interdisciplinary perspective. *Front Endocrinol (Lausanne)* (2017) 8:96. doi: 10.3389/fendo.2017.00096

29. Heidt T, Sager HB, Courties G, Dutta P, Iwamoto Y, Zaltsman A, et al. Chronic variable stress activates hematopoietic stem cells. *Nat Med* (2014) 20:754–8. doi: 10.1038/nm.3589

30. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. *Nature* (2012) 487:325–9. doi: 10.1038/nature11260

31. von Haaren B, Haertel S, Stumpp J, Hey S, Ebner-Priemer U. Reduced emotional stress reactivity to a real-life academic examination stressor in students participating in a 20-week aerobic exercise training: A randomised controlled trial using ambulatory assessment. *Psychol Sport Exerc* (2015) 20:67–75. doi: 10.1016/j.psychsport.2015.04.004

32. Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE, et al. Enhancing cardiac rehabilitation with stress management training: a randomized, clinical efficacy trial. *Circulation* (2016) 133:1341–50. doi: 10.1161/ CIRCULATIONAHA.115.018926

33. Fields JZ, Walton KG, Schneider RH, Nidich S, Pomerantz R, Suchdev P, et al. Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of maharishi Vedic medicine. *Am J Cardiol* (2002) 89:952–8. doi: 10.1016/S0002-9149(02)02245-2

34. Levine GN, Lange RA, Bairey-Merz CN, Davidson RJ, Jamerson K, Mehta PK, et al. Meditation and cardiovascular risk reduction: a scientific statement from the American heart association. *J Am Heart Assoc* (2017) 6:e002218. doi: 10.1161/JAHA.117.002218

35. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for americans. *JAMA* (2018) 320:2020–8. doi: 10.1001/jama.2018.14854

36. Wrase J, Makris N, Braus DF, Mann K, Smolka MN, Kennedy DN, et al. Amygdala volume associated with alcohol abuse relapse and craving. *Am J Psychiatry* (2008) 165:1179–84. doi: 10.1176/appi.ajp.2008.07121877

37. Daviet R, Aydogan G, Jagannathan K, Spilka N, Koellinger PD, Kranzler HR, et al. Associations between alcohol consumption and gray and white matter volumes in the UK biobank. *Nat Commun* (2022) 13:1175. doi: 10.1038/s41467-022-28735-5